Cite
HARVARD Citation
Schachter, J. et al. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 390 (10105), pp. 1853-1862. [Online].